Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04514484 · OUTCOME

Human Immunodeficiency Virus (HIV) Viral Loads

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV · Source last updated 2026-05-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
copies/mL
Interval / dispersion
Not reported
Time frame
At Treatment Cycle 11

What was measured

HIV viral loads at treatment Cycle 11.

Analysis population: Treated patients who provided samples for HIV viral load testing.

Groups in this outcome

Treatment (Cabozantinib S-malate, Nivolumab)

Patients receive cabozantinib s-malate PO QD on days 1-28 of each cycle and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI as well as blood sample collection throughout the trial. Biospecimen Collection: Undergo blood sample collection Cabozantinib S-malate: Given PO Computed Tomography: Undergo CT Magnetic Resonance Imaging: Undergo MRI Nivolumab: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Cabozantinib S-malate, Nivolumab)1

Reported measurements

Source class 1
Values in copies/mL · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Cabozantinib S-malate, Nivolumab)NANot reportedNot reportedNot reportedThe value indicated for HIV is less than 20 (undetectable) - no exact number available
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        The value indicated for HIV is less than 20 (undetectable) - no exact number available
        group Id
        OG000
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    units
    Participants
description
HIV viral loads at treatment Cycle 11.
groups
  1. description
    Patients receive cabozantinib s-malate PO QD on days 1-28 of each cycle and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI as well as blood sample collection throughout the trial. Biospecimen Collection: Undergo blood sample collection Cabozantinib S-malate: Given PO Computed Tomography: Undergo CT Magnetic Resonance Imaging: Undergo MRI Nivolumab: Given IV
    id
    OG000
    title
    Treatment (Cabozantinib S-malate, Nivolumab)
param Type
NUMBER
population Description
Treated patients who provided samples for HIV viral load testing.
reporting Status
POSTED
time Frame
At Treatment Cycle 11
title
Human Immunodeficiency Virus (HIV) Viral Loads
type
SECONDARY
unit Of Measure
copies/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice